Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Open accessThe DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, as the MAPK pathway has normal sensitivity to insulin, hyperinsulinemia activates the MAPK pathway, promoting vascular smooth muscle cell growth and activating inflammatory pathways, such as IkB/NF-kB and JNK [107,108].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [108]
In the citing paper
“These macrophages, in combination with adipocytes and lipid-infiltrated muscle tissues, stimulate the secretion of proinflammatory cytokines, particularly TNF-α and IL-6, while reducing the release of protective adiponectin, thereby evoking systemic chronic inflammation that directly damages the vascular endothelium and, in, turn exacerbates IR and atherosclerosis (56).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 1
- Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page
Cited by
Items 401–500 of 535
SOKUEVA, K. Y., & Ivanova, L. A. (2022) · Современные проблемы науки и образования · doi:10.17513/spno.31940
Pan, J. H., Yang, B., Wang, Z., Tang, L., Jia, P., Yang, S., & Zeng, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1994972/v1
Wanionok, N. E. (2022) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/148089
Zhao, X., Cai, Q., Dong, L., Zhang, X., Wang, C., Wang, S., Liu, L., & Hu, A. (2023) · Sleep And Breathing · doi:10.1007/s11325-023-02791-7 · Cited by 1
“They may lead to chronic inflammation and development of AS [57–60].”
BackgroundAtallah, R. B., Aboelwafa, H. O., & Elkhodary, S. B. (2023) · Research Square · doi:10.21203/rs.3.rs-2698497/v1
Wang, X., Wang, J., Ren, J., Zhang, X., Wang, J., Wang, Y., Hu, Y., Zhang, Y., He, C., Xue, W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2823691/v1
Швед, М. І., & Овсійчук, Р. М. (2023) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2023.v.i1.13734
Insulin resistance and cardiovascular diseases: focus on common in pathogenesis and treatment.
Zhuravlyova, L., Rogachova, T., Sokolnikova, N. V., & Yankevich, O. O. (2023) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2023.02.046
Immunometabolism mRNA expression phenotypes and reprogramming of CD14 in T2DM with or without CVD
Bendaya, I., Jemaa, A. B., Sahraoui, G., Kharrat, M., Sdiri, W., & Oueslati, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110665
Review of Related Research on Type 2 Diabetes Related Macroangiopathy
李, 珊. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1392097
Which sub-compartments of fat mass and fat-free mass are related to blood viscosity factors?
Brun, J. ‐., Varlet‐Marie, E., Myzia, J., Vachoud, L., Marion, B., Roques, C., de Mauverger, É. R., & Mercier, J. G. (2023) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-238118 · Cited by 2
“Abdominal adiposity is known to be associated to a decrease in insulin sensitivity which results into alterations of lipid profile, blood pressure and glucose homeostasis [10].”
Current Status of Research on Cardiovascular Risk in Patients with Non-Alcoholic Fatty Liver Disease
娜迪热, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112445
Hrekova, T. A., Melnikova, O. V., & Kadzharian, Y. V. (2023) · Current issues in pharmacy and medicine science and practice · doi:10.14739/2409-2932.2023.3.286820
“Such alteration has been confirmed by the capacity of beta-cells to maintain metabolic homeostasis and normoglycemia through an increase in insulin secretion and/or a rise in the beta-cell number within the PIs [14,15].”
Backgroundİnsülin 100 Yıllık Mucize Hormon
Cerit, E. T., Barlas, T., Atalar, K., Bahçelioğlu, M., Kaplanoğlu, G. T., Seymen, C. M., Erdem, H. B., Ergün, M. A., Demir, Ö., Gülbahar, Ö., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.871
Study the relationship between zinc transporter 8 and others parameters in atherosclerosis patients
Mahdi, B., & Auda, F. M. (2024) · AIP conference proceedings · doi:10.1063/5.0200468
Evaluación del modelo de homeostasis (HOMA) en Centro Médico Docente La Trinidad
Vilera, N., Aure, G., & Marchan, A. (2023) · Diabetes actual · doi:10.61156/2023.1.1.003
Khan, K. M., Quazi, S., & Wanjari, A. (2024) · National Journal of Community Medicine · doi:10.55489/njcm.150420243789 · Cited by 1
“27 Most of the research that made up this review showed a positive and substantial correlation be-tween T2DM and CVD, and the TG/HDL ratio.”
BackgroundZhao, X., Zhao, H., Chen, R., Li, N., Li, J., Zhou, J., Yan, S., Liu, C., Zhou, P., Chen, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4331946/v1
Li, H., Jiang, G., Mao, M., Yu, W., Luo, J., Li, S., Xie, L., Bai, X., Xu, Y., Jiang, Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4845175
Shafi, O., Irfan, S., Ahmed, A., Maheshwari, G., Kumar, R., Raveena, Rajpar, R., & Saeed, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4498525/v1
Type 2 Diabetes: Facts and Fallacies
Amin, M. N. (2024) · Ibrahim Cardiac Medical Journal · doi:10.3329/icmj.v13i1.73818
Liu, J., Yang, S., Le, C. W., Qin, Y., & Li, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4479122/v1
Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease
Li, Q. I. N., JunRu, W. U., YuQing, L. I. U., YingXuan, G. O. N. G., & JingJing, C. A. I. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0098 · Cited by 1
Progress of Triglyceride Glucose Index in Lesion Severity and Prognosis of Acute Coronary Syndromes
Li, S., & Hu, P. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.128019
姜, 珊. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482349
Тамерланович, Ц. Т., Skripnikova, I. A., Kosmatova, O. V., & Куруглиевна, Я. Э. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202427121128
Anisimova, M., Кононенко, Н. М., & Чікіткіна, В. В. (2024) · ScienceRise Pharmaceutical Science · doi:10.15587/2519-4852.2024.318509
Yao, X., Liang, L., Yang, M., Liang, Z., Piao, Y., Chen, J., Liang, Y., & Fang, X. (2025) · Research Square · doi:10.21203/rs.3.rs-5831890/v1
Villegas, P. I. A., & Pedreáñez, A. B. (2025) · European journal of health research · doi:10.32457/ejhr.v11i1.2870
Kawamoto, R., Kikuchi, A., Ninomiya, D., Kumagi, T., & Abe, M. (2025) · Cureus · doi:10.7759/cureus.81773
“IR is recognized as a risk factor for both microvascular and macrovascular complications [2] and is associated with the onset of hyperglycemia, increased blood pressure [3], nonalcoholic fatty liver disease [4], atherogenic dyslipidemia [5], and a variety of other malignancies [6].”
汪, 园. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541101
Shi, M., Fan, S., Sun, L., Chen, X., & Zhang, G. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.04.018 · Cited by 1
“This in fl amma-tory cascade accelerates oxidative stress, LDL oxidation, and cholesterol deposition, exacerbating arterial stiffness and atherosclerosis [51,52].”
Guo, S.-H., Xu, J., Gong, Y.-Q., Hu, W., Li, C., & Lü, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1574238
Liu, M., Liu, F., Diljhumal, A., Yang, J., wang, Y., Ye, M., Jia, T., & Gao, Y. (2025) · medRxiv · doi:10.1101/2025.05.04.25326947
Rerkasem, A., Mangklabruks, A., Buranapin, S., Sony, K., Inpankaew, N., Rerkasem, R., Pongtam, S., Phirom, K., & Rerkasem, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322502
Matsuo, T., Mitsui, S., Takata, G., Higaki, S., Inai, R., Mochizuki, S., Yoshihara, A., & Akimitsu, K. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.135006
Nieuwoudt, A., Strauss, K.-L. E., Phoswa, W. N., & Mokgalaboni, K. (2025) · Viruses · doi:10.3390/v17070894
“It is worth noting that insulin resistance promotes a proinflammatory and prothrombotic status; collectively, these factors contribute to atherosclerosis and CIMT progression [65,73].”
Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
Khoury, S. E., Harake, S. N. A., Youssef, T., Risk, C. E., Helou, N., Doumet, N. M., Aramouni, K., Azar, S. T., Najjar, S. M., & Ghadieh, H. E. (2025) · Livers · doi:10.3390/livers5030034 · Cited by 1
Principles of diet therapy for sarcopenic obesity: A review
Pavlovskaya, E. V., Кislyak, O. A., & Starodubova, A. V. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.07.203270 · Cited by 4
Han, B., Ma, J., Liu, S., Fu, C., Zhang, H., Luo, Y., Wang, F., & Zeng, Q. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1627246
“After redefining HTN as ≥ 130/80 mmHg, the eGDR showed a linear negative correlation with CAS progression (Supplementary Figure S1).”
InfluentialXin, Y., Peng, N., Xin, C.-Y., Liao, J.-R., Hu, X., Dong, Y., & Zhang, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.108671 · Cited by 2
Yerokhovych, V., Karpenko, O., Ilkiv, Y., GURIANOV, V., Krasnienkov, D. S., Sulaieva, O., Komisarenko, I., Falalyeyeva, T. M., & Kobyliak, N. M. (2025) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.25.03266-3
Almahdiansyah, R., Theodora, T., & Kusumaningtyas, M. J. (2025) · Calvaria Medical Journal. · doi:10.30742/cmj.v3i1.121
Lu, A., & Xu, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-7556978/v1
Song, X., Chen, M., Wang, X., & Niu, H. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1660031
“Insulin resistance induces chronic inflammation and endothelial dysfunction, promoting foam cell formation, atherosclerosis, and the development of vulnerable plaques (33, 34).”
Al-Baldawi, S. Q., Al‐Hakeim, H. K., Hamam, H., & Khémiri, I. (2025) · Biotechnology Reports · doi:10.1016/j.btre.2025.e00932
“Insulin resistance (IR) and metabolic syndrome contribute to the pathophysiology of atherosclerosis partly by suppressing nitric oxide synthesis [82].”
He, R. Q., & Zhao, K. (2025) · Medicine · doi:10.1097/md.0000000000045652
“[43] eGDR incorporates body size, HbA1c levels, and hypertension status, all routinely assessed upon admission of people with MAFLD, hence, it is particularly suitable for early diagnosis of MAFLD.”
Ouyang, J., Lu, W., Fan, Y., Jiang, Z., Du, Q., & Liu, D. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012954 · Cited by 1
Cardiometabolic indices as predictors of clinical outcomes in palliative care patients
Üçdal, M. T., Ekingen, E., Yurtsever, K., Celik, M. E., & Kuru, S. B. (2026) · PLoS ONE · doi:10.1371/journal.pone.0338562
“Insulin resistance, the core abnormality captured by the TyG component, drives a cascade of metabolic derangements including increased lipolysis, hepatic triglyceride synthesis, endothelial dysfunction, oxidative stress, and systemic inflammation—all implicated in adverse outcomes [29].”
López‐González, Á. A., Ramírez‐Manent, J. I., Rifá, E. M.-A., Paublini, H., Sánchez, C. M., & López, P. J. T. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500803
Tian, X., Chen, S., Xu, Q., Xia, X., Zhang, Y., Wang, P., Wu, S., & Wang, A. (2024) · Figshare · doi:10.6084/m9.figshare.26653416
Chen, W., Shi, S., Tu, J., Liao, L., Liao, Y., Chen, K., Chen, L., & Huang, R. (2022) · Figshare · doi:10.6084/m9.figshare.21269174
Li, F., Wang, Y., Shi, B., Sun, S., Wang, S., Pang, S., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26664136
Huang, X., Cheng, H., Yuan, S., Ling, Y., Tan, S., Tang, Y., Niu, C., & Lyu, J. (2023) · Figshare · doi:10.6084/m9.figshare.24465061
Zhang, Y., Xia, Z., Cai, X., Su, X., Jin, A., Mei, L., Jing, J., Wang, S., Meng, X., Li, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24804254
정, 미., Yi, S.-W., An, S. J., Yi, J.-J., Ihm, S.-H., Han, S., Ryu, K.-H., Jung, H. O., & Youn, H.-J. (2022) · Figshare · doi:10.6084/m9.figshare.19608172
Zhang, S., Cao, C., Han, Y., Hu, H., & Zheng, X. (2024) · Figshare · doi:10.6084/m9.figshare.26713430
Wang, Y., Liu, T., Li, Y., Zhang, K., Fan, H., Ren, J., Li, J., Li, Y., Li, X., Wu, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22662344
Fang, Y., Dou, A., Shen, Y., Li, T., Liu, H., Cui, Y., & Xie, K. (2024) · Figshare · doi:10.6084/m9.figshare.26753623
Wu, T.-W., Chou, C.-L., Cheng, C.-F., Lu, S.-X., Wu, Y.-J., & Wang, L. (2023) · Figshare · doi:10.6084/m9.figshare.22626001
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Figshare · doi:10.6084/m9.figshare.21485387
Kim, S., Lee, J.-W., Lee, Y., Song, Y., & Linton, J. A. (2023) · Figshare · doi:10.6084/m9.figshare.23625555
Zhao, Q., Cheng, Y.-J., Xu, Y.-K., Zhao, Z.-W., Liu, C., Sun, T.-N., & Zhou, Y.-J. (2021) · Figshare · doi:10.6084/m9.figshare.16640904
Yang, X., Wang, G., Jing, J., Wang, A., Zhang, X., Jia, Q., Meng, X., Zhao, X., Liu, L., Li, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19327292
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Figshare · doi:10.6084/m9.figshare.21485396
Liu, C., Liu, X., Ma, X., Cheng, Y., Sun, Y., Zhang, D., Zhao, Q., & Zhou, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21293505
Li, F., Wang, Y., Shi, B., Sun, S., Wang, S., Pang, S., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26664133
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Figshare · doi:10.6084/m9.figshare.21485399
Li, F., Wang, Y., Shi, B., Sun, S., Wang, S., Pang, S., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26664139
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Figshare · doi:10.6084/m9.figshare.21485393
Yang, Y., Ma, M., Zhang, J., Jin, S., Zhang, D., & Lin, X. (2023) · Figshare · doi:10.6084/m9.figshare.24532005
Kim, S., Lee, J.-W., Lee, Y., Song, Y., & Linton, J. A. (2023) · Figshare · doi:10.6084/m9.figshare.23625552
Guo, X., Shen, R., Yan, S., Su, Y., & Ma, L. (2023) · Figshare · doi:10.6084/m9.figshare.22622845
Zhou, Z., Liu, Q., Zheng, M., Zuo, Z., Zhang, G., Shi, R., & Wu, T. (2024) · Figshare · doi:10.6084/m9.figshare.26074138
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Figshare · doi:10.6084/m9.figshare.21485402
Qian, J., Huang, G., & Mao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26129804
Zhao, Q., Cheng, Y.-J., Xu, Y.-K., Zhao, Z.-W., Liu, C., Sun, T.-N., & Zhou, Y.-J. (2021) · Figshare · doi:10.6084/m9.figshare.16640907
Chen, W., Shi, S., Tu, J., Liao, L., Liao, Y., Chen, K., Chen, L., & Huang, R. (2022) · Figshare · doi:10.6084/m9.figshare.21269171
Yan, F., Yan, S., Wang, J., Cui, Y., Chen, F., Fang, F., & Cui, W. (2022) · Figshare · doi:10.6084/m9.figshare.21485390
Qian, J., Huang, G., & Mao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26129690
Tao, S., Yu, L., Li, J., Xie, Z., Huang, L., Yang, D., Tan, Y., Zhang, W., Huang, X., & Xue, T. (2024) · Figshare · doi:10.6084/m9.figshare.26646499
Wang, L., Wang, Y., Liu, R., Xu, L., Zhong, W., Li, L., Wang, C., He, C., Fu, C., & Wei, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26552924
Platelets, Vascular Inflammation, and Atherosclerosis
Gawaz, M. P., Rohlfing, A.-K., & Castor, T. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_6
Mao, B.-B., Xiang, Y., Luo, P.-Q., Li, D., Guo, Y., Meng, X., Kan, R., Pan, L.-M., He, Y., Wang, S.-Y., et al. (2025) · Current Medical Science · doi:10.1007/s11596-025-00146-9
“Furthermore, IR is closely associated with lipid metabolism disorders and hypercoagulability, which promote lipid deposition and thrombosis, ultimately contributing to atherosclerosis and other cardiovascular events [54].”
Cai, H., Liu, Y., Wang, M., Wang, J., Xie, Y., & Hu, Y. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-025-10684-0 · Cited by 1
Deng, J., Shi, H., Wu, D., Zhu, J., Zeng, S., Xie, Y., Hu, Y., Xie, L., & Mao, T. (2026) · BMC Neurology · doi:10.1186/s12883-025-04600-y · Cited by 1
The Impact of Insulin Resistanceon the Onset and Prognosis of Ischemic Stroke in Young Adults
彭, 燕. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161189
Qiu, X., Sha, J., Li, Y., Ding, T., Fang, J., Song, W., Zhao, Y., Mangmang, P., Shen, L., Huang, H., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-025-02848-4 · Cited by 1
Yamamoto, H., Ishii, A., & Kihara, S. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66011 · Cited by 1
“…diluted cDNA (1 µL) were then added to 10 µL of total reaction volume containing SYBR Green (5 µL) using the SYBR Premix Ex Taq II (Takara, Shiga, Japan) as described common underlying factors, such as visceral obesity and insulin resistance, which may synergistically promote atherogenesis 7, 8) .”
Zhao, X., Chen, R., Li, J., Zhou, J., Li, N., Xue, L., Yan, S., Liu, C., Zhou, P., Chen, Y., et al. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s560787
Huang, Z., Zou, Q., & Lin, Y. (2026) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_511_25
Liu, P., Wang, H., Han, X., Jin, R., Li, J., Song, S., Zhao, W., Song, Y., Pan, Y., Ma, X., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02881-x
Li, S., Yan, C., Wu, M., Wang, T., Zhu, L., Yu, C., Zhang, W., Zhou, W., Bao, H., & Cheng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1764481
“Concurrently, compensatory hyperinsulinemia activates pro-atherogenic MAPK pathways, promoting vascular smooth muscle cell proliferation and in fl ammation (34, 35).”
Xu, W., Wu, S., Chen, S., Guo, Y., & Xia, Y. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101401 · Cited by 1
“Yet, an extensive literature supports that inflammation is a prominent putative mediator of insulin resistance, which can further contribute to atherosclerosis, metabolic syndrome and adverse cardiovascular disease (CVD) [31,32].”
Guo, Q., Pan, Y., Zhao, X., Yin, S., Lu, Y., Jiang, Y., Cheng, Y., & Liu, Y. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104620
Insulin resistance and ischemic stroke
Пизова, Н. В., & Pizov, A. V. (2026) · Russian neurological Journal · doi:10.30629/2658-7947-2025-30-6-4-10
Huang, Y., Zhang, R., Zhou, Y., Li, D., Ni, W.-J., 万艳慧, Tao, J., Bo, X., Qi, X., & Zhong, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1745428
Tarabay, A., Halaby, T., Amin, H. E., Sharaf-Edin, H. M., Abu-Naeima, E., & Elshenoufy, M. G. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00616-z
Wang, X., Qin, S., Peng, B., Xiang, H., Tao, Y., Guo, C., & Lu, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-46225-2
魏, 麟. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641496
Metadata
- Authors
- Di Pino, A., & DeFronzo, R. A.
- Affiliations
- Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- DeFronzo, Ralph A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-03
- Volume
- 40
- Issue
- 6
- Pages
- 1447-1467
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7445419
- OpenAlex
- W2945554427
- Cited by
- 535
- References
- 344
- Citations by year
- 2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK-24092-38)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.